Cargando…
Siglec-5 is a novel marker of critical limb ischemia in patients with diabetes
Critical Limb Ischemia (CLI) is common but uncommonly diagnosed. Improved recognition and early diagnostic markers for CLI are needed. Therefore, the aim of our study was to identify plasma biomarkers of CLI in patients with type 2 diabetes mellitus (T2DM). In this study, antibody-coated glass slide...
Autores principales: | Li, Ju-yi, Yang, Xiao-yan, Wang, Xiu-fang, Jia, Xiong, Wang, Zhong-jing, Deng, Ai-ping, Bai, Xiang-li, Zhu, Lin, Li, Bing-hui, Feng, Zi-bo, Li, Ye, Wang, Ling, Jin, Si |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595823/ https://www.ncbi.nlm.nih.gov/pubmed/28900239 http://dx.doi.org/10.1038/s41598-017-11820-x |
Ejemplares similares
-
MiR-323b-5p acts as a novel diagnostic biomarker for critical limb ischemia in type 2 diabetic patients
por: Cheng, Biao, et al.
Publicado: (2018) -
Circulating MicroRNA-4739 May Be a Potential Biomarker of Critical Limb Ischemia in Patients with Diabetes
por: Li, Ju-yi, et al.
Publicado: (2018) -
Critical Limb Ischemia
por: Schanzer, Andres, et al.
Publicado: (2010) -
The intriguing roles of Siglec family members in the tumor microenvironment
por: Jiang, Kui-Ying, et al.
Publicado: (2022) -
Terminal Epitope-Dependent Branch Preference of Siglecs Toward N-Glycans
por: Wang, Shuaishuai, et al.
Publicado: (2021)